Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
Aura Biosciences, Inc. update: Bel-sar Phase 3 trial enrolled; topline data due 2H 2027. Click for more on AURA stock.
SeekingAlpha23 gün önceAURA
Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With Jefferies
- Sec Filing
Benzinga24 gün önceAURA
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Aura Biosciences (NASDAQ:AURA) with a Buy and lowers the price target from $24 to $18.
Benzinga24 gün önceAURA
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 29.73 percent. This is a 2.13 percent decrease over losses of $(0.47) per share
Benzinga24 gün önceAURA